ArticleJACC. Case reports2026
Early Degeneration of a Next-Generation Mitral Bioprosthesis in the Tricuspid Position Treated With Valve-in-Valve.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reading TTVR Mechanically: Three Questions This Mini-Focus Helps Us Ask.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBioprosthetic tricuspid valve replacement is increasingly performed, but long-term durability data are limited. The Edwards Mitris Resilia valve, designed for the mitral position, has been used off-label in the tricuspid position, with scarce evidence of outcomes. CASE SUMMARY: We report 2 patients who developed early (<2-year) structural valve degeneration of the Mitris Resilia bioprosthesis in the tricuspid position. Both presented with symptomatic severe intraprosthetic tricuspid regurgitation. Given the prohibitive surgical risk of redo sternotomy, we opted for valve-in-valve (ViV) transcatheter tricuspid valve replacement (TTVR) using the Edwards Sapien 3 Ultra Resilia transcatheter heart valve. Both procedures were successful, with no residual regurgitation or paravalvular leak. DISCUSSION: To our knowledge, this is the first reported series of early Mitris Resilia structural valve degeneration in the tricuspid position. The cases highlight potential concerns about the durability of bioprostheses in the tricuspid position, especially in congenital heart disease or redo settings. Valve-in-valve tricuspid valve replacement with balloon-expandable transcatheter valves proved to be feasible, safe, and effective, preventing high-risk surgical reoperation. Early intervention is crucial to avoid irreversible right ventricular dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.